# Chemotherapy

Source: https://onco.cc/fronts/chemotherapy/  
OnCo record `chemotherapy` (Front). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Drugs that kill fast-dividing cells. Still the backbone of many cures, and now the warhead inside smarter drugs.

## Summary

Chemotherapy collects the cytotoxic drugs that kill fast-dividing cells: platinums, taxanes, anthracyclines, antimetabolites and topoisomerase inhibitors. These agents remain curative in several cancers and now serve as the payloads inside antibody-drug conjugates, so progress lies in dosing, sequencing, biomarker-guided de-escalation and toxicity mitigation rather than in new cytotoxics alone. Technologies that point here include cytotoxic chemotherapy, platinum agents, topoisomerase-I inhibitors, autologous and tandem stem cell transplant, PET-adapted therapy, HIPEC and PIPAC, TACE, chronotherapy and metabolic therapy. Scalp cooling and the company PharmaMar also link to this section.

## Fields

- Kind: Front
- Last checked: 2026-09-04

## Sources

- NCI: Chemotherapy to treat cancer: https://www.cancer.gov/about-cancer/treatment/types/chemotherapy

## Connected records

- journals: [Cancer chemotherapy and pharmacology](https://onco.cc/journals/cancer-chemotherapy-and-pharmacology/), [Gan to kagaku ryoho. Cancer & chemotherapy](https://onco.cc/journals/gan-to-kagaku-ryoho/), [Journal of oncology pharmacy practice](https://onco.cc/journals/journal-of-oncology-pharmacy-practice/)
- technologies: [Acupuncture and acupressure for chemotherapy nausea](https://onco.cc/technologies/acupuncture-nausea/), [Acupuncture for chemotherapy-induced neuropathy](https://onco.cc/technologies/acupuncture-chemotherapy-neuropathy/), [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [Bimatoprost for eyelash and eyebrow regrowth](https://onco.cc/technologies/bimatoprost-eyelash-regrowth/), [Cannabinoids for chemotherapy nausea (dronabinol, nabilone, medical cannabis)](https://onco.cc/technologies/cannabinoids-nausea/), [Chronotherapy: timing treatment to the body clock](https://onco.cc/technologies/chronotherapy/), [Closed-system transfer devices for hazardous drugs (PhaSeal, ChemoLock, Equashield)](https://onco.cc/technologies/closed-system-transfer-devices/), [Creams and lotions tried to prevent chemotherapy hair loss](https://onco.cc/technologies/hair-topical-prevention-agents/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [DPYD genotyping and DPD phenotyping before fluoropyrimidines](https://onco.cc/technologies/dpyd-genotyping/), [Electrochemotherapy devices (Cliniporator)](https://onco.cc/technologies/electrochemotherapy-devices/), [Exercise during chemotherapy and radiotherapy](https://onco.cc/technologies/exercise-during-chemotherapy/), [Fasting and fasting-mimicking diets around chemotherapy](https://onco.cc/technologies/fasting-mimicking-diet/), [Frozen gloves, socks and compression for taxane nail and nerve damage](https://onco.cc/technologies/frozen-gloves-compression-taxane/), [Generic oncology drug supply and shortage mitigation](https://onco.cc/technologies/generic-drug-shortage-response/), [Generic sterile injectables (the 2023 platinum shortage)](https://onco.cc/technologies/sterile-injectable-generics-manufacturing/), [Ginger for chemotherapy nausea](https://onco.cc/technologies/ginger-nausea/), [Glutamine for mucositis and neuropathy](https://onco.cc/technologies/glutamine-mucositis-neuropathy/), [GMP, inspections, Form 483s and warning letters](https://onco.cc/technologies/pharmaceutical-gmp-inspections/), [Hearing after platinum and cranial radiotherapy in a developing child](https://onco.cc/technologies/rejuv-paed-hearing/), [Hearing and tinnitus after platinum chemotherapy](https://onco.cc/technologies/hearing-after-platinum-chemotherapy/), [Heart function after anthracyclines, trastuzumab and chest radiotherapy](https://onco.cc/technologies/cardiotoxicity-surveillance-recovery/), [HIPEC / PIPAC (intraperitoneal chemotherapy)](https://onco.cc/technologies/hipec/), [HIPEC perfusion pumps and PIPAC nebulisers](https://onco.cc/technologies/hipec-pipac-devices/), [Hypoxia-activated prodrugs](https://onco.cc/technologies/hypoxia-activated-therapy/), [Infusion pumps, ports, and ambulatory chemotherapy devices](https://onco.cc/technologies/infusion-devices-vascular-access/), [Metabolic therapy: starving the tumour of a nutrient](https://onco.cc/technologies/metabolic-therapy/), [Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss](https://onco.cc/technologies/minoxidil-chemotherapy-alopecia/), [Nails after chemotherapy: lifting, ridges and discolouration](https://onco.cc/technologies/nail-changes-after-chemotherapy/), [Nerve damage from chemotherapy: what recovers, and what helps](https://onco.cc/technologies/cipn-recovery-and-treatment/), [Oncology pharmacy automation and compounding robots](https://onco.cc/technologies/pharmacy-automation/), [Oral cryotherapy (ice chips) to prevent mucositis](https://onco.cc/technologies/oral-cryotherapy-mucositis/), [Oral solid dose manufacturing (tablets and capsules)](https://onco.cc/technologies/oral-solid-dose-manufacturing/), [Ovarian function after chemotherapy: who recovers, and when](https://onco.cc/technologies/ovarian-function-after-chemotherapy/), [PET-adapted (response-adapted) therapy](https://onco.cc/technologies/pet-adapted-therapy/), [Pharmacogenomic testing before chemotherapy](https://onco.cc/technologies/oncology-pharmacogenomics/), [Platinum agents](https://onco.cc/technologies/platinum/), [Probiotics for chemotherapy and radiotherapy diarrhoea](https://onco.cc/technologies/probiotics-treatment-diarrhoea/), [Protecting the heart during anthracycline treatment: dexrazoxane, beta blockers and ACE inhibitors](https://onco.cc/technologies/anthracycline-cardioprotection/), [Scalp care during and after cancer treatment](https://onco.cc/technologies/scalp-care-cancer-treatment/), [Scalp cooling (cold caps: DigniCap, Paxman)](https://onco.cc/technologies/scalp-cooling/), [Small-molecule API synthesis](https://onco.cc/technologies/small-molecule-api-synthesis/), [Tandem autologous transplant](https://onco.cc/technologies/tandem-transplant/), [The cumulative dose that decides whether it comes back](https://onco.cc/technologies/rejuv-recovery-cumulative-dose/), [The heart after anthracyclines and chest radiotherapy in childhood](https://onco.cc/technologies/rejuv-paed-heart/), [Thinking and memory after cancer treatment: what is measurable, and what helps](https://onco.cc/technologies/cognitive-impairment-after-cancer-treatment/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/), [TPMT and NUDT15 genotyping before thiopurines](https://onco.cc/technologies/tpmt-nudt15-genotyping/), [Transarterial chemoembolisation (TACE)](https://onco.cc/technologies/tace/), [UGT1A1 genotyping before irinotecan](https://onco.cc/technologies/ugt1a1-genotyping/), [What comes back after treatment, treatment by treatment](https://onco.cc/technologies/rejuv-recovery-matrix/)
- companies: [B. Braun](https://onco.cc/companies/b-braun/), [Baxter International](https://onco.cc/companies/baxter/), [BD (Becton, Dickinson and Company)](https://onco.cc/companies/becton-dickinson/), [Biostar Pharmaceuticals](https://onco.cc/companies/biostar-pharmaceuticals/), [Cipla](https://onco.cc/companies/cipla/), [Civica Rx](https://onco.cc/companies/civica-rx/), [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/), [Delcath Systems](https://onco.cc/companies/delcath/), [Dr. Reddy's Laboratories](https://onco.cc/companies/dr-reddys/), [Fresenius Kabi](https://onco.cc/companies/fresenius-kabi/), [Gemini Therapeutics](https://onco.cc/companies/gemini-therapeutics/), [German Lymphoma Alliance](https://onco.cc/companies/german-lymphoma-alliance/), [InnoPharmax](https://onco.cc/companies/innopharmax/), [Intas Pharmaceuticals (Accord Healthcare)](https://onco.cc/companies/intas/), [International Extranodal Lymphoma Study Group](https://onco.cc/companies/ielsg/), [Lupin](https://onco.cc/companies/lupin/), [Luye Pharma Group](https://onco.cc/companies/luye-pharma/), [medac](https://onco.cc/companies/medac/), [Natco Pharma](https://onco.cc/companies/natco/), [Nippon Kayaku](https://onco.cc/companies/nippon-kayaku/), [Omnicell](https://onco.cc/companies/omnicell/), [Oncopeptides](https://onco.cc/companies/oncopeptides/), [PharmaMar](https://onco.cc/companies/pharmamar/), [Phaxiam Therapeutics (formerly ERYtech Pharma)](https://onco.cc/companies/phaxiam/), [Shasqi](https://onco.cc/companies/shasqi/), [WuXi AppTec](https://onco.cc/companies/wuxi-apptec/), [Zydus Lifesciences](https://onco.cc/companies/zydus/)
- roadmaps: [Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs](https://onco.cc/roadmaps/chemotherapy-roadmap/), [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/), [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/), [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/), [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/), [Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch](https://onco.cc/roadmaps/prostate-roadmap/), [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- key papers: [A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer](https://onco.cc/key-papers/paper-espac-1-chemoradiotherapy-chemotherapy-resected-pancreatic-nejm-2004/), [Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma](https://onco.cc/key-papers/paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025/), [Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study (QUASAR)](https://onco.cc/key-papers/paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007/), [Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7)](https://onco.cc/key-papers/paper-quenet-prodige-7-hipec-peritoneal-colorectal-lancet-oncol-2021/), [Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance/CALGB 50303](https://onco.cc/key-papers/paper-calgb-50303-da-epoch-r-vs-r-chop-jco-2019/), [Duration of adjuvant chemotherapy for stage III colon cancer (the IDEA collaboration)](https://onco.cc/key-papers/paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018/), [DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer](https://onco.cc/key-papers/paper-dynamic-nejm-2022/), [Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial](https://onco.cc/key-papers/paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017/), [Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy](https://onco.cc/key-papers/paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017/), [FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of TRIBE](https://onco.cc/key-papers/paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015/), [Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER)](https://onco.cc/key-papers/paper-flyer-four-vs-six-cycles-r-chop-lancet-2019/), [GETUG-AFU 15: androgen deprivation alone or with docetaxel in non-castrate metastatic prostate cancer](https://onco.cc/key-papers/paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013/), [Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial](https://onco.cc/key-papers/paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025/), [Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma](https://onco.cc/key-papers/paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022/), [Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma](https://onco.cc/key-papers/paper-moertel-levamisole-fluorouracil-adjuvant-colon-nejm-1990/), [Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23)](https://onco.cc/key-papers/paper-conroy-prodige-23-neoadjuvant-folfirinox-rectal-lancet-oncol-2021/), [Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017/), [Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)](https://onco.cc/key-papers/paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004/), [PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study](https://onco.cc/key-papers/paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019/), [PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group](https://onco.cc/key-papers/paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017/), [Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study](https://onco.cc/key-papers/paper-smile-chemotherapy-nk-t-cell-lymphoma-jco-2011/), [Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma: results from the phase III, randomized POLARGO trial](https://onco.cc/key-papers/paper-polargo-polatuzumab-r-gemox-dlbcl-jco-2026/), [Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial (FOxTROT)](https://onco.cc/key-papers/paper-foxtrot-preoperative-chemotherapy-colon-jco-2023/), [Randomized phase III trial of ibrutinib and R-CHOP in non-germinal centre B-cell diffuse large B-cell lymphoma (PHOENIX)](https://onco.cc/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/), [Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03](https://onco.cc/key-papers/paper-trog-99-03-radiotherapy-systemic-therapy-early-follicular-jco-2018/), [Randomized trial of TAS-102 for refractory metastatic colorectal cancer (RECOURSE)](https://onco.cc/key-papers/paper-mayer-recourse-tas-102-nejm-2015/), [Short-course radiotherapy followed by chemotherapy before total mesorectal excision versus preoperative chemoradiotherapy in locally advanced rectal cancer (RAPIDO)](https://onco.cc/key-papers/paper-bahadoer-rapido-short-course-radiotherapy-lancet-oncol-2021/), [STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis](https://onco.cc/key-papers/paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016/), [SWOG 9916: docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer](https://onco.cc/key-papers/paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004/), [TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer](https://onco.cc/key-papers/paper-tannock-tax-327-docetaxel-prednisone-nejm-2004/), [Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT)](https://onco.cc/key-papers/paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023/), [TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel](https://onco.cc/key-papers/paper-de-bono-tropic-cabazitaxel-lancet-2010/), [VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801](https://onco.cc/key-papers/paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007/)
- trials: [AHL2011](https://onco.cc/trials/ahl2011/), [Alliance/CALGB 50303](https://onco.cc/trials/calgb-50303/), [ARCHED](https://onco.cc/trials/arched/), [Big Lung Trial](https://onco.cc/trials/big-lung-trial/), [ENRICH](https://onco.cc/trials/enrich/), [EORTC/LYSA/FIL H10](https://onco.cc/trials/eortc-h10/), [FLYER](https://onco.cc/trials/flyer/), [FOxTROT](https://onco.cc/trials/foxtrot/), [GHSG HD10](https://onco.cc/trials/hd10/), [GHSG HD16](https://onco.cc/trials/hd16/), [GHSG HD18](https://onco.cc/trials/hd18/), [GOYA](https://onco.cc/trials/goya/), [IELSG-19](https://onco.cc/trials/ielsg-19/), [JCOG9801](https://onco.cc/trials/jcog9801/), [MRC COIN](https://onco.cc/trials/coin/), [POLAR BEAR](https://onco.cc/trials/polar-bear/), [POLARGO](https://onco.cc/trials/polargo/), [PRIMA-CNS](https://onco.cc/trials/prima-cns/), [QUASAR](https://onco.cc/trials/quasar/), [REMARC](https://onco.cc/trials/remarc/), [SCOT](https://onco.cc/trials/scot/), [SHINE](https://onco.cc/trials/shine/), [SMILE](https://onco.cc/trials/smile-enktl/), [TROG 99.03](https://onco.cc/trials/trog-99-03/)
- ideas: [A live stock-out map for essential chemotherapy drugs](https://onco.cc/ideas/idea-acc-chemo-stockout-early-warning/), [A non-profit manufacturer for shortage-prone generic chemotherapy](https://onco.cc/ideas/idea-cost-nonprofit-generic-oncology/), [Choose regimens by infusion-chair hours, not just efficacy, where chairs are the constraint](https://onco.cc/ideas/idea-acc-infusion-sparing-regimens/), [Home administration of selected chemotherapy and immunotherapy for older and frail patients](https://onco.cc/ideas/idea-acc-home-chemotherapy-older-patients/), [Nurse-led chemotherapy day units with a doctor on a screen](https://onco.cc/ideas/idea-acc-nurse-led-chemotherapy-units/), [Oncology pharmacists as protocol prescribers for supportive care and dose adjustments](https://onco.cc/ideas/idea-acc-oncology-pharmacist-prescribing/), [Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer](https://onco.cc/ideas/idea-prostate-randomise-the-sequence-not-only-the-drugs/), [Randomised evidence for the T-cell lymphomas, including the ones that are not in Europe or North America](https://onco.cc/ideas/lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas/), [Share vials and round doses to stop throwing away expensive drug](https://onco.cc/ideas/idea-cost-vial-sharing-dose-rounding/), [Take ctDNA-guided de-escalation beyond stage II, and stop escalating on a positive result until a trial says it helps](https://onco.cc/ideas/idea-crc-ctdna-de-escalation-beyond-stage-ii/), [The drugs that cure lymphoma, and the places that do not have them](https://onco.cc/ideas/lymphoma-ev-the-drugs-that-cure-and-the-places-without-them/), [Watch for the cancer changing cell type before the biopsy says neuroendocrine, and act on it](https://onco.cc/ideas/idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine/)
- drugs: [Melphalan hepatic delivery system](https://onco.cc/drugs/hepzato/)
- people: [Alberto Gabizon](https://onco.cc/people/alberto-gabizon/), [Donald Pinkel](https://onco.cc/people/donald-pinkel/), [Emil "Tom" Frei III](https://onco.cc/people/emil-frei/), [Emil J Freireich](https://onco.cc/people/emil-freireich/), [Gertrude Elion](https://onco.cc/people/gertrude-elion/), [Jane Cooke Wright](https://onco.cc/people/jane-cooke-wright/), [Robert Sandler](https://onco.cc/people/robert-sandler/), [Sidney Farber](https://onco.cc/people/sidney-farber/), [Yechezkel Barenholz](https://onco.cc/people/yechezkel-barenholz/)
- terms: [7+3 induction chemotherapy](https://onco.cc/terms/seven-plus-three/), [ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)](https://onco.cc/terms/abvd-beacopp/), [Alkylating agents and antimetabolites](https://onco.cc/terms/alkylating-agent/), [Anagen effluvium (chemotherapy hair loss)](https://onco.cc/terms/hair-anagen-effluvium/), [Anthracyclines (doxorubicin, epirubicin)](https://onco.cc/terms/anthracycline/), [Autologous stem cell transplant (ASCT)](https://onco.cc/terms/autologous-transplant/), [Backbone, add-on and monotherapy](https://onco.cc/terms/backbone-add-on/), [Chemoradiation (chemoradiotherapy, CRT)](https://onco.cc/terms/chemoradiation/), [Chemotherapy](https://onco.cc/terms/chemotherapy-term/), [Conditioning regimen (myeloablative, reduced-intensity)](https://onco.cc/terms/conditioning-regimen/), [Consolidation therapy](https://onco.cc/terms/consolidation-therapy/), [De-escalation, escalation and response-adapted therapy](https://onco.cc/terms/de-escalation/), [Dose-dense and metronomic chemotherapy](https://onco.cc/terms/dose-dense-chemotherapy/), [Doublet, triplet and quadruplet regimens](https://onco.cc/terms/doublet-triplet/), [Downstaging and conversion therapy](https://onco.cc/terms/downstaging/), [Eyebrow and eyelash loss (madarosis)](https://onco.cc/terms/hair-brows-and-lashes/), [FLOT regimen (perioperative chemotherapy for gastric cancer)](https://onco.cc/terms/flot-term/), [FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX](https://onco.cc/terms/folfox-family/), [HIPEC (hyperthermic intraperitoneal chemotherapy)](https://onco.cc/terms/hipec-procedure/), [Hypomethylating agents (azacitidine, decitabine)](https://onco.cc/terms/hma/), [Induction therapy](https://onco.cc/terms/induction-therapy/), [Intraperitoneal (IP) chemotherapy](https://onco.cc/terms/intraperitoneal-chemotherapy/), [Intrathecal therapy (lumbar puncture, Ommaya reservoir)](https://onco.cc/terms/intrathecal-therapy/), [Leptomeningeal disease](https://onco.cc/terms/leptomeningeal-disease/), [Limited-stage vs extensive-stage (small-cell lung cancer)](https://onco.cc/terms/limited-extensive-stage/), [Maintenance therapy](https://onco.cc/terms/maintenance-therapy/), [Persistent chemotherapy-induced alopecia](https://onco.cc/terms/alopecia-persistent-chemotherapy/), [Platinum-sensitive / platinum-resistant](https://onco.cc/terms/platinum-sensitivity/), [R-CHOP (lymphoma chemoimmunotherapy)](https://onco.cc/terms/r-chop/), [Rechallenge and retreatment](https://onco.cc/terms/rechallenge/), [Regimen and cycles](https://onco.cc/terms/chemotherapy-regimen/), [Regrowth after chemotherapy (chemo curls)](https://onco.cc/terms/hair-regrowth-after-chemotherapy/), [Relapsed / refractory (R/R)](https://onco.cc/terms/relapsed-refractory/), [Salvage therapy](https://onco.cc/terms/salvage-therapy/), [Taxanes (paclitaxel, docetaxel, nab-paclitaxel)](https://onco.cc/terms/taxane/), [Total neoadjuvant therapy (TNT, rectal cancer)](https://onco.cc/terms/total-neoadjuvant-therapy/), [VRd and Dara-VRd (myeloma induction regimens)](https://onco.cc/terms/vrd/)
- institutions: [Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service](https://onco.cc/institutions/auckland-city-hospital/), [Butaro Cancer Center of Excellence](https://onco.cc/institutions/butaro-cancer-center/), [Children's Cancer Hospital Egypt 57357](https://onco.cc/institutions/cche-57357/), [Hamad Medical Corporation / National Center for Cancer Care and Research](https://onco.cc/institutions/hamad-medical-corporation/), [Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi](https://onco.cc/institutions/homi-bhabha-cancer-hospital-varanasi/), [Hospital Universitari i Politècnic La Fe](https://onco.cc/institutions/la-fe-valencia/), [Indiana University Melvin and Bren Simon Comprehensive Cancer Center](https://onco.cc/institutions/iu-simon/), [Istanbul University Institute of Oncology](https://onco.cc/institutions/istanbul-oncology-institute/), [King Hussein Cancer Center](https://onco.cc/institutions/khcc/), [Mays Cancer Center at UT Health San Antonio](https://onco.cc/institutions/mays-cancer-center/), [National Cancer Grid of India](https://onco.cc/institutions/national-cancer-grid/), [National Cancer Institute, Cairo University](https://onco.cc/institutions/nci-cairo/), [Ramathibodi Hospital, Mahidol University](https://onco.cc/institutions/ramathibodi-hospital/), [Royal Adelaide Hospital](https://onco.cc/institutions/royal-adelaide-hospital/), [Ruijin Hospital, Shanghai Jiao Tong University](https://onco.cc/institutions/ruijin-hospital/), [Seoul St. Mary's Hospital](https://onco.cc/institutions/seoul-st-marys-hospital/), [Sydney Children's Hospitals Network / Children's Cancer Institute](https://onco.cc/institutions/sydney-childrens-hospitals-network/), [Tata Medical Center, Kolkata](https://onco.cc/institutions/tata-medical-center-kolkata/), [Tawam Hospital](https://onco.cc/institutions/tawam-hospital/), [Uganda Cancer Institute](https://onco.cc/institutions/uganda-cancer-institute/), [University Hospitals Birmingham / University of Birmingham Cancer Research Centre](https://onco.cc/institutions/birmingham-cancer-centre/), [Velindre Cancer Centre](https://onco.cc/institutions/velindre-cardiff/)

---
JSON: https://onco.cc/api/v1/entities/chemotherapy.json